Safety profile of vunakizumab in elderly patients with moderate-to-severe plaque psoriasis: a post-hoc analysis. [PDF]
Front Med (Lausanne)Mu T +5 more
europepmc +1 more source
A 76-week real-world multidimensional analysis of guselkumab in moderate to severe plaque psoriasis: a retrospective cohort study based on Chinese clinical practice standards. [PDF]
Front ImmunolHu R +10 more
europepmc +1 more source
PASI post-test analysis results
A report on post-test analyses using codes of partners’ choice, based on as-built PASI configuration data and actual test parameters and boundary conditions, being aware of test outcomes.
openaire +1 more source
Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a <i>post-hoc</i> analysis of a phase 3 trial. [PDF]
Front ImmunolLi Q +8 more
europepmc +1 more source
PASI facility description for PASTELS
A report describing PASI configuration used in ...
openaire +1 more source
Efficacy and safety of vunakizumab in moderate-to-severe plaque psoriasis patients with different body mass index: a <i>post hoc</i> analysis based on a phase III trial. [PDF]
Front PharmacolWang X, Li L.
europepmc +1 more source
Bibliografia angloamerikkalaisesta akateemisesta sotahistorian tutkimuksesta [PDF]
Tuunainen, Pasi
core
Evaluating Risankizumab's Long-Term Effects in Psoriasis Using Optical Coherence Tomography. [PDF]
Dermatol Ther (Heidelb)Zirpel H +9 more
europepmc +1 more source
Abrocitinib Treatment of Atopic Dermatitis or Eczema in Patients with Coexistent or Prior Psoriasis: Three Cases with Literature Review. [PDF]
Clin Cosmet Investig DermatolChen X, Ji H, Xiong J, Chen S, Cai T.
europepmc +1 more source
Serum Semaphorin Alterations in Psoriasis: Links to Metabolic Status Rather than Disease Severity. [PDF]
MetabolitesBaran A +6 more
europepmc +1 more source